Cartesian Therapeutics, Inc. RNAC
6.36 USD -0.52 (-7.63%)
At closeNov 12, 2026, 4:00 PM EST
6.36 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
6.12 Day range 6.82
5.60 52-week range 11.00
- YTD
- -11.86%
- 1 year
- -16.16%
News
zacks.com Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High? The consensus price target hints at a 379.6% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward…
benzinga.com Cartesian Therapeutics Q3 EPS $(0.38) Beats $(0.95) Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.95) by 60 percent. This is a 72.46 percent increase over losses of…
globenewswire.com Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.- benzinga.com Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
benzinga.com Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatmentMedian…- benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
- benzinga.com Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
benzinga.com New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
benzinga.com BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translationPlans…- benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
- benzinga.com Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40 Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $42 to $40.
benzinga.com Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an…- benzinga.com HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $30 to $25.
benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.- benzinga.com Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.88) by 65.91 percent. This is a 114.71 percent decrease over…
- benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
- benzinga.com Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.
- benzinga.com Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
benzinga.com CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over…
benzinga.com Insights into Cartesian Therapeutics Q4 Earnings - benzinga.com Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42 Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.
benzinga.com Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.- benzinga.com HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $30 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $40 to $30.
benzinga.com Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
benzinga.com Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday - benzinga.com BTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44 BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $42 to $44.
- benzinga.com Cartesian Therapeutics Data From Phase 2 Study Of Descartes-08 Demonstrates 100% Lupus Low Disease Activity State Response Rate In Participants With Systemic Lupus Erythematosus Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the…
- benzinga.com Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.84) by 63.31 percent. This is a 22.12 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.82) by 160.98 percent. This is a 7.41 percent decrease over…
benzinga.com AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.- benzinga.com Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38 Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.
- benzinga.com Cartesian Begins Phase 3 Trial of New Cell Therapy for Myasthenia Gravis Without Chemo Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first…
benzinga.com With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.- benzinga.com Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40 Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $41 to $40.
- benzinga.com Cartesian Therapeutics Q1 EPS $(0.68) Beats $(0.71) Estimate, Sales $1.10M Beat $785.71K Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.71) by 4.23 percent. This is a 93.52 percent increase over losses…
benzinga.com Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - benzinga.com Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family
- benzinga.com Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session